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Abstract
Objective—The risk-benefit profile of antidepressant medications in bipolar disorder is
controversial. When conclusive evidence is lacking, expert consensus can guide treatment
decisions. The International Society for Bipolar Disorders (ISBD) convened a task force to seek
consensus recommendations on the use of antidepressants in bipolar disorders.
Method—An expert task force iteratively developed consensus through serial consensus-based
revisions using the Delphi method. Initial survey items were based on systematic review of the
literature. Subsequent surveys included new or reworded items and items that needed to be
rerated. This process resulted in the final ISBD Task Force clinical recommendations on
antidepressant use in bipolar disorder.
Results—There is striking incongruity between the wide use of and the weak evidence base for
the efficacy and safety of antidepressant drugs in bipolar disorder. Few well-designed, long-term
trials of prophylactic benefits have been conducted, and there is insufficient evidence for treatment
benefits with antidepressants combined with mood stabilizers. A major concern is the risk for
mood switch to hypomania, mania, and mixed states. Integrating the evidence and the experience
of the task force members, a consensus was reached on 12 statements on the use of antidepressants
in bipolar disorder.
Conclusions—Because of limited data, the task force could not make broad statements
endorsing antidepressant use but acknowledged that individual bipolar patients may benefit from
antidepressants. Regarding safety, serotonin reuptake inhibitors and bupropion may have lower
rates of manic switch than tricyclic and tetracyclic antidepressants and norepinephrine-serotonin
reuptake inhibitors. The frequency and severity of antidepressant-associated mood elevations
appear to be greater in bipolar I than bipolar II disorder. Hence, in bipolar I patients
antidepressants should be prescribed only as an adjunct to mood-stabilizing medications.
The efficacy and safety of antidepressant drug treatment in bipolar disorder is the subject of
long-standing debate based on a scientific literature that is limited and inconsistent (1–6).
The sparseness of high-quality clinical research hampers the formulation of sound clinical
recommendations on the use of antidepressants in the treatment of bipolar disorder (7–12).
We propose that a consensus formed by the experience and judgment of clinical and
academic bipolar disorder experts, guided by the available research findings, may help in
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developing at least tentative treatment recommendations as additional research is awaited.
Accordingly, the International Society for Bipolar Disorders (ISBD) appointed Dr. Vieta to
assemble a task force of international experts to review the evidence base for benefits and
risks of antidepressant treatment in bipolar disorder and to formulate clinical
recommendations based on the consensus development process. This report represents a
consensus statement from this endeavor.
Method
Consensus Methods
The ISBD Task Force was made up of a panel of global experts on bipolar disorder, selected
according to an objective procedure based on a Scopus search of citations on the specific
topic of antidepressant use in bipolar disorder (number of citations per candidate during the
past 3 years). The most cited authors (including several ISBD nonmembers) and some
additional authors from key geographical areas were identified and invited by e-mail to
participate; 76% agreed to participate. An introductory meeting was held at the ISBD
biennial congress (Istanbul, March 2012), where task force procedures were reviewed and
agreed upon. These procedures focused on the discussion and integration of findings from
peer-reviewed published research findings on the topic, including reviews and meta-
analyses, as well as clinical trial reports. An expert coauthor (I.P.) was appointed to develop
a first draft of a systematic review, to be circulated after initial review by the senior author
(E.V.). The aims of the task force were to conduct a thorough and balanced review of
research findings and to integrate them into an expert consensus, based on clinical
experience and judgment, as well as research evidence, and to provide a synthesis of current
knowledge supporting clinical recommendations for this important and timely topic. The
final section of this report, which summarizes consensus statements, was achieved through a
face-to-face meeting, personal and group e-mail correspondence, and serial iterative
revisions of the report, in order to provide a final guide on the use of antidepressants in
bipolar disorder. Funding for this international project was provided solely by the Spanish
government.
Search Strategy
We performed an extensive literature search on PubMed, using the following search terms,
limited to human studies: antidepressant* AND (mania[ti] OR manic[ti]); antidepressant*
AND (bipolar[ti] AND depressi*[ti]); antidepressant* AND (mixed [ti] AND state*[ti]);
antidepressant* AND bipolar disorder AND maintenance[ti]; antidepressant* AND bipolar
disorder AND comorbid*[ti]; antidepressant* AND switch AND (manic OR mania OR
hypomani*); antidepressant* AND (cycle acceleration OR phase shift OR cycle frequen*);
and antidepressant* AND (suicid*[ti] OR self-kill*[ti] OR self-harm*[ti]).
We considered first-generation norepinephrine-serotonin reuptake inhibitors (SNRIs),
including tricyclic and tetracyclic antidepressants; monoamine oxidase (MAO) inhibitors;
and the modern antidepressants, including the dopamine-norepinephrine reuptake inhibitor
bupropion, serotonin reuptake inhibitors (SSRIs), modern SNRIs, the norepinephrine-
serotonin autoreceptorspecific antagonists mianserin and mirtazapine; the atypical, mixed
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monoamine-transporter inhibitors trazodone and nefazodone; and the melatonin M1 and M2
receptor agonist and 5-HT2c receptor antagonist agomelatine.
We address here only antidepressant medications, not the treatment of bipolar depression in
general. Hence, we did not include alternative or experimental agents such as
sulfoadenosine-L-methionine; Hypericum perforatum (St. John’s wort); various mood
stabilizers and antipsychotics with some evidence of antidepressant efficacy (e.g., lithium,
lamotrigine, quetiapine, olanzapine, lurasidone); glutamatergic modulators including glycine
and its analogues; ketamine, memantine, and other N-methyl-D-aspartate (NMDA)
inhibitors; azapirone anxiolytics (buspirone, gepirone); stimulants (e.g., amphetamines,
methylphenidate); the antinarcolepsy agents modafinil and armodafinil; and direct dopamine
receptor agonist antiparkinsonian agents such as pramipexole. We also did not include
nonpharmacological treatments, such as ECT, transcranial magnetic stimulation, vagus
nerve stimulation, deep brain stimulation, intense light therapy, or psychological
interventions.
Systematic Review Methods
Each report considered was rated for methodological quality according to the Jadad scale
(13) as poor (scores of 0–2) or acceptable-good (scores of 3–5; see the data supplement that
accompanies the online edition of this article). Each report was rated A, B, C, or D for
overall quality, as recommended by the Australian National Health and Medical Research
Council (14), save for the applicability criterion (see the data supplement and Table 1).
Included references may contain additional reports for particular questions and statements.
Meta-analyses and reviews were used as evidence to support information that could not be
drawn from individual studies. Figure 1 outlines how reports were selected.
Delphi Method
To add a table of recommendations at the end of the systematic review, we conducted a
survey using the Delphi method (15–17). Statements on antidepressant use in bipolar
disorder that could be useful to clinicians were derived from the content of the literature
search and classified into six common domains: acute treatment; maintenance treatment;
monotherapy; switch to mania, hypomania, or mixed states and rapid cycling; use in mixed
states; and drug class. Three survey rounds were conducted to develop consensus. The first
survey included open-ended questions at the end of each section inviting participants to add
comments and suggestions by e-mail. Later rounds were conducted online using
eSurveysPro.com. The survey was sent to task force members for anonymous responses.
Panel members rated survey items ranging from “essential” to “should not be included.” We
calculated proportions of respondents rating each item. Survey items were classified as
endorsed, rerated, or rejected.
Endorsed items—Items rated by at least 80% of ISBD experts as essential or important
were included in the ISBD recommendations.
Rerated items—Items rated as essential or important by 65%79% of panel experts were
included in the next survey for rerating after considering feedback from first-round results.
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Panel members could decide whether they wanted to maintain or change their previous
rating on these relatively controversial items. Items were rerated only once; if they did not
achieve the criterion for endorsement, they were rejected.
Rejected items—Items that were not included by at least 65% of panelists on the first
round were rejected and excluded.
The initial survey included 25 items. The second survey included 23 items. The briefer third
survey consisted of five items that needed rerating.
Twelve of the initial 25 items were endorsed and formed the section of the ISBD clinical
recommendations of antidepressant use in bipolar disorder (Table 2).
Results
Search Results
A summary of our literature search and review is presented in Figure 1.
Efficacy
Antidepressant monotherapy—Antidepressant monotherapy is widely regarded as
contraindicated for patients with bipolar disorder because of the weak evidence for efficacy
and the potential risk for excessive mood elevation (switches). An elevated risk of mood
switching was first observed in early trials that compared imipramine monotherapy, lithium
monotherapy, lithium plus imipramine, and placebo (18, 19). Imipramine monotherapy was
followed by more manic episodes than combination therapy with imipramine and lithium
and was not superior to lithium in preventing depressive episodes.
To date, the largest randomized placebo-controlled trial assessing antidepressant
monotherapy in bipolar depression has been the EMBOLDEN II (Efficacy of Monotherapy
Seroquel in Bipolar Depression) study (20), in which paroxetine was included as an active
comparator to quetiapine and placebo in 740 acutely depressed patients with bipolar I or II
disorder. Compared with placebo, paroxetine did not result in significant symptomatic
improvement as rated on the Montgomery-Åsberg Depression Rating Scale (MADRS) in
either bipolar type, whereas quetiapine (at 300 and 600 mg/day) separated from placebo
without evidence of a dose effect. The study is limited by its use of amoderate, fixed dose of
paroxetine (20 mg/day). A small randomized controlled trial of escitalopram monotherapy
(21), an uncontrolled trial of fluoxetine (22), and a randomized controlled trial of fluoxetine
or lithium monotherapy and placebo (23) found some support for the efficacy of these drugs
in depressed bipolar II patients, with no evidence of mood switching.
Conclusions: Overall, available clinical trials do not provide adequate support for the
efficacy of antidepressant monotherapy in acute bipolar depression, but the evidence base is
poor (D) and inconclusive (Table 1). Although the evidence might be rated C for depression
in bipolar II patients, the studies focusing on such cases are marred by methodological
shortcomings and possibly selective reporting.
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Adjunctive antidepressants: short-term efficacy in acute depression—Short-
term trials of adjunctive antidepressant treatment have reported mixed results, perhaps best
exemplified by the contrasting findings in the two largest placebo-controlled trials carried
out to date. The first of these (24) compared the efficacy and safety of olanzapine
monotherapy (5–20 mg/day, N=370) to placebo (N=377) in depressed bipolar I patients in
an 8-week randomized double-blind trial with a small exploratory arm with several dosages
of olanzapine-fluoxetine combinations. The olanzapine-fluoxetine combinations were more
effective than olanzapine alone or placebo in improving MADRS depression scores at weeks
4–8. Limitations of the study included its lack of a fluoxetine monotherapy arm and a
substantial dropout rate (38.5%).
In the second trial (25), depressed bipolar I or II patients (N=366) receiving treatment with a
mood stabilizer (lithium, valproate, carbamazepine, or other antimanic agents approved by
the U.S. Food and Drug Administration, alone or in combination) were randomly assigned
to receive adjunctive antidepressants (bupropion or paroxetine) or placebo for up to 26
weeks. Adjunctive antidepressants were no more effective than placebo at any time, and
overall, 23.5% of patients given an antidepressant and 27.3% given placebo met criteria for
enduring recovery. Limitations of the trial included its use of already well treated patients,
its long duration, and the study requirement for sustained improvement.
A smaller placebo-controlled study (26) also found no significant differences in efficacy
among paroxetine, imipramine, or placebo as adjuncts tomood stabilizers. Conversely, a
single-blind randomized trial (27) of short duration and lacking a control found significant
improvement after 6 weeks in depressed bipolar I and II patients treated with mood
stabilizers plus paroxetine or venlafaxine (28).
Several meta-analyses have statistically combined data from some or all of these
antidepressant studies. One such study (29) found higher response rates with an
antidepressant compared with placebo and no increase in risk of manic switch (29), but it
suffered from being heavily weighted by one large olanzapine-fluoxetine study (24). A later
meta-analytic review (30) found nonsignificant differences between antidepressants and
placebo in response and remission rates (p=0.06), which would have been even less
favorable if the analysis had used a random-effects rather than a fixed-effects model (31).
Another recent random-effects meta-analysis (32) found superiority of antidepressants over
placebo (relative risk=1.43, 95% CI=1.11–1.84; z=2.76, p=0.006).
Finally, a large naturalistic study (33) found short-term antidepressant treatment (with or
without mood stabilizers) in acute major depressive episodes to be similarly effective in a
total of 1,036 patients with bipolar I disorder, bipolar II disorder, and unipolar depression.
Regarding possible predictors of short-term response to antidepressants in depressed bipolar
patients, two naturalistic trials in acutely depressed bipolar I and II patients (34, 35) found
that the most significant predictors of beneficial responses were previous response to
antidepressants and a less severe illness course. In a naturalistic follow-up study (36), short-
term recovery from depression in bipolar I or II disorder was neither hastened nor prolonged
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when antidepressants were added to a mood stabilizer in the presence of syndromal or
subsyndromal hypomanic symptoms.
Conclusions: Overall, the available evidence (category B) supports the efficacy of the
olanzapine-fluoxetine combination in bipolar depression, indicates a lack of positive effects
of paroxetine or bupropion added to mood stabilizers, and is otherwise inconsistent. The
overall evidence quality of predictors of response to antidepressants is rated D, because of
inconclusiveness and possible bias of findings (Table 1).
Adjunctive antidepressants: long-term maintenance studies—For modern
antidepressants, only two randomized controlled trials lacking placebo controls have
examined the effects of continuing antidepressant treatment after favorable short-term
responses in bipolar I depression (37, 38); notably, both trials involved patients who showed
favorable short-term responses to antidepressant treatment. In one trial, depressed bipolar I
or II patients who responded to initial treatment with venlafaxine, bupropion, or sertraline
added to standard mood stabilizers after 2 months (50%–60% of each group) continued
these treatments for up to 1 year, and only 15%–25%had no further episodes (37, 39). In the
second trial (38), among 70 depressive bipolar I or II patients who had remitted for ≥8
weeks during treatment with a standard mood stabilizer plus an antidepressant (usually an
SSRI, venlafaxine, or bupropion), antidepressant continuation showed nonsignificantly less
severe depressive symptoms but a significant delay in recurrence of new depressive
episodes, except that rapid-cycling patients experienced more depressive recurrences with an
antidepressant.
A nonrandomized uncontrolled trial (40), again involving patients showing favorable short-
term responses, examined the effect of continuing or discontinuing antidepressant treatment
for bipolar I and II patients who had remitted from a depressive episode for ≥6 weeks after
addition of an antidepressant to a mood stabilizer. Over 1 year of follow-up, patients who
discontinued antidepressant treatment experienced a shorter latency to depressive relapse
(χ2=9.63, p=0.002) and were more likely to relapse (70% compared with 36%).
In contrast to these findings, a meta-analysis of long-term antidepressant efficacy in bipolar
depression (41) found that compared with mood stabilizer treatment alone, adjunctive
antidepressants provided little protection from depression and tended to increased
maniahypomania, resulting in an unfavorable risk-benefit ratio for long-term antidepressant
use in bipolar I disorder.
Examining possible predictors of long-term responsiveness to adjunctive antidepressants in
the Stanley Foundation Bipolar Network study (42), the research team found that depressed
bipolar patients who achieved an initial response during 10 weeks of adjunctive
antidepressant treatment (bupropion, sertraline, or venlafaxine) were more likely to maintain
response with the same continuation regimen. Similarly, in a randomized double-blind
placebo-substitution study with fluoxetine monotherapy in bipolar II depression (23), initial
response to antidepressant treatment was associated with fewer relapses if antidepressant
treatment was continued for up to 50 weeks.
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Conclusions: Long-term trials involving addition of antidepressants to ongoing mood-
stabilizing treatments are scant and have yielded ambiguous, inconclusive findings, despite a
moderately favorable quality score (C) for the evidence and despite reliance on samples
enriched for probable short-term antidepressant response. For predictors of response, the
lack of adequate controls and reliance on enriched patient samples led to a D rating of
available evidence (Table 1).
Antidepressant use in mania and mixed states—Despite a lack of controlled trials
of adjunctive antidepressants during manic, hypomanic, or mixed episodes, most clinicians
avoid their use during mixed episodes for fear of worsening mania, and without improving
mixed-state depressive symptoms (36, 43–46). Indeed, no evidence of efficacy is available
for antidepressants in mania or mixed states.
Nevertheless, in an observational study, 21.9% of 2,416 manic patients were taking
antidepressants at baseline. Predictors of continuing antidepressants for up to 24 months of
follow-up were mixed states, more previous depressive episodes, rapid cycling, and higher
rates of depressive and anxiety symptoms at baseline (47, 48).
Similarly, two retrospective observational studies (49, 50) found that a history of mixed
episodes was associated with use of antidepressants, especially SNRIs and SSRIs—both
lifetime and during the 6 months preceding an index mixed episode. Moreover, in a study of
a large U.S. insurance claims database (51), antidepressant treatment was identified in 32%
of 2,126 patients with bipolar I disorder following a recent manic or mixed episode, with
more rehospitalizations within 12 months with than without an antidepressant.
Conclusions: Overall, the lack of controlled studies of antidepressant use in mania and
mixed states points to a D quality rating of available evidence (Table 1).
Safety
Antidepressants and mood switching—The assessment of antidepressant-associated
mood switches into hypomania, mania, or mixed states is a particularly controversial topic.
The principal difficulty lies in attributing causality, as mood elevations and changes in cycle
frequency occur unpredictably in the natural course of bipolar disorder, making it difficult to
distinguish spontaneous from antidepressant-induced switching (52). Randomized trials
evaluating the risk of switches with antidepressant treatment with and without a mood
stabilizer are few and difficult to interpret, owing to methodological limitations (53–57).
Moreover, the definition of mood switching lacks consensus among experts (58). In an
attempt to clarify the terminology of antidepressant-associated mood elevations, the ISBD
reached consensus in recommending use of the term “treatment-emergent affective switch”
instead of antidepressant-induced switch (59), to emphasize association without implying
causality. The ISBD definition of treatment-emergent affective switch provides operational
criteria that consider factors such as timing, duration, and severity of mood changes in
attributing probable causation to antidepressant treatment. Obviously, since these criteria are
very recent, they have not yet been widely tested or adopted.
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Despite these definitional shortcomings, a notably consistent finding from randomized
controlled trials of antidepressants in bipolar patients is that of differences among types of
antidepressants in their association with mood switches (54). For example, a small 8-week
prospective double-blind trial comparing adjunctive bupropion or desipramine in bipolar
depression (60) found hypomania or mania in five of 10 desipramine-treated patients but in
only one of nine bupropion-treated patients. However, several placebo-controlled
randomized controlled trials did not find elevated switch rates with SSRIs or bupropion,
either as adjuncts to mood stabilizers or as monotherapy (54). In a previously described 6-
month double-blind placebo-controlled trial (25), rates of mood elevations were
indistinguishable (10.1% compared with 10.7%) between subjects receiving a mood
stabilizer plus an antidepressant (bupropion or paroxetine, N=179) and those receiving a
mood stabilizer plus placebo (N=197).
Even in monotherapy, it is not clear whether SSRIs increase the risk of mood switching. In
one randomized controlled trial (20), paroxetine (20 mg/day) was not associated with more
mood switching than placebo. In a 12-month trial (37), the risk of antidepressant-associated
switching ranked was 9% for sertraline, 10% for bupropion, and 29% for venlafaxine. A
short-term (6–week) study (27) also found more mood switching with venlafaxine than with
paroxetine in depressed bipolar I and II patients. These findings suggest that mood switching
may be limited to certain antidepressant classes, such as the triand tetracyclics and
venlafaxine, and that dosages, cotreatments, exposure times, types of bipolar patients, and
criteria for “switching” may each have a role. Several metaanalyses have evaluated
antidepressant-associated switch risk. In an early meta-analysis (61), the rate of treatment-
emergent switch occurred substantially more often with tri- and tetracyclics (11.2%) than
with SSRIs (3.7%) or placebo (4.2%). A subsequent meta-analysis (29) found that, with the
exception of tri- and tetracyclics and venlafaxine, switching was uncommon. Another
review (54) found that treatment with or without antidepressants did not increase the risk of
switching in bipolar patients (types I or II) compared with rates of spontaneous switching
(15.3% and 13.8%, respectively). Nevertheless, tri- and tetracyclics carried a higher risk for
new maniahypomania than SSRIs or MAO inhibitors. Another review (30) found that SSRIs
and bupropion were not associated with more switching than placebo during short-term
treatment, but noted that studies employing sensitive criteria to define switching reported
higher switch rates for tri- and tetracyclics and venlafaxine than for SSRIs and bupropion.
Regarding the issue of whether mood stabilizers protect against antidepressant treatment-
associated mood switching, a comprehensive review (54) found a lack of evidence that
treatment with mood stabilizers protects against mood elevation in bipolar patients, with or
without antidepressant co-treatment, but noted a lack of appropriate controls or
randomization with which to make an adequate assessment. However, one study (62) found
a higher risk of mood switching in bipolar disorder than in unipolar depression (2.50%/week
compared with 0.275%/week), even though 70% of the bipolar patients were receiving
antidepressant-mood stabilizer combinations, whereas most unipolar patients received an
antidepressant alone. Questions about antidepressant-associated switching include that of the
risks associated with many specific antidepressants and effects of dosage, for which there is
insufficient evidence. For example, most studies of SSRIs have involved sertraline or
paroxetine, and effects of MAO inhibitors are virtually unknown (54, 63–65).
Pacchiarotti et al. Page 8






















Besides the effect of antidepressant type, the risk of switch may also vary according to
bipolar type. An early study (63) suggested that patients with bipolar I disorder are at higher
risk of switching than those with bipolar II disorder, a finding that was supported in a post
hoc analysis from the Stanley Foundation Bipolar Network study (66). Four previously
discussed studies also suggested a low risk of switching for bipolar disorder II patients, even
when treated with antidepressant monotherapy (21–23, 67).
A systematic meta-analytic review of 13 prospective studies (68) supported the impression
that bipolar I patients have a higher antidepressant-associated switch rate than bipolar II
patients (relative risk=1.78, p=0.002), although bipolar I cases involved mania as well as the
hypomania found with bipolar II disorder. These findings suggest greater clinical safety with
use of antidepressants in patients with bipolar II disorder (69), although even hypomania can
be problematic.
Most information regarding clinical correlates of risk of mood switching during
antidepressant treatment comes from retrospective or post hoc analyses. Results of two such
studies (36, 45) suggest that even subsyndromal manic symptoms at the start of
antidepressant treatment as an adjunct to mood stabilizer treatment were associated with a
later increased risk of switching into hypomanic or manic episodes, worsening of manic
symptoms, and higher rates of unsatisfactory response to antidepressants.
Conversely, another study (70) found that a history of suicide attempt and high scores on the
aggressive-disruptive behavior item of the Young Mania Rating Scale, but not the presence
of subsyndromal hypomanic symptoms, at study entry were associated with a higher risk of
mood switching among antidepressant-treated depressed bipolar patients.
A large long-term study (71) found that among patients in a major depressive episode, those
meeting criteria for bipolar features (72, 73) showed a higher risk of later episodes of
hypomania or mania and greater mood lability during antidepressant treatment. Finally, a
history of antidepressant-associated mood switching, lower rates of previous clinical benefit
from antidepressant treatment, and multiple previous antidepressant trials have been
associated with subsequent mood switches, generally more severe illness, and worse long-
term outcomes (74–76).
Regarding antidepressant monotherapy and the risk of treatment-emergent affective
switches, one study (77) found that depressed bipolar patients first exposed to antidepressant
monotherapy had higher switch rates and more suicide attempts than those treated with
antidepressant- mood stabilizer combinations. Finally, the picture regarding genetic
characteristics as predictors of mood switching in bipolar patients treated with
antidepressants (78–80) is still unclear.
Conclusions: The risk of mood switching is considered to be higher and more severe in
bipolar I than bipolar II patients and somewhat greater with tri- and tetracyclics (and perhaps
some SNRIs) than with most modern antidepressants. The quality of available evidence on
these topics is rated C (Table 1).
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Are newly emerging or increasing irritability and agitation during
antidepressant treatment a form of mood switching?—Antidepressant treatment in
bipolar disorder is sometimes associated with new or worsening irritability or agitation that
may or may not be related to more fully expressed mood switching (58). Such responses
have been termed “antidepressant-associated chronic irritable dysphoria” and may be more
likely in bipolar patients with a history of antidepressant-related mood switching (81). In
addition, many cases of agitated depression in bipolar patients, often with new-onset
insomnia, impulsivity, and suicidal preoccupations, have been associated with new
antidepressant treatment (44). Such states can be managed effectively by discontinuing
antidepressants and using mood stabilizers or other antimanic agents (36, 82, 83). Other
associations include increased risk of antidepressant-associated hypomania with previous
episodes with mixed features (defined as three or more hypomanic symptoms) during
antidepressant treatment (84).
Conclusions: Despite interesting proposals, the question of whether worsening of
depression, including emergence or worsening of irritability or agitation with
antidepressants, is related to the phenomenon of antidepressant-associated mood switching
remains unsettled. The overall evidence level for this topic is D (Table 1).
Antidepressants and cycle acceleration—Another controversial question is whether
antidepressants can accelerate episode frequency or induce rapid cycling in bipolar patients
(52). Several anecdotal case series suggest that antidepressant treatment may induce or
prolong rapid cycling in initially depressed bipolar patients (85–88). In a prospective
longitudinal study comparing the frequency and pattern of mood changes between bipolar
outpatients treated with antidepressants or not (89), those treated with antidepressants were
depressed on twice as many days as those not so treated (29.0% compared with 14.8%).
In a large unblinded but randomized study of effects of receiving or not receiving continued
antidepressant treatment after recovery from acute depression (38), a previous rapid cycling
course predicted 3.1 times more depressive recurrences with continued antidepressant
treatment (1.29 compared with 0.42 episodes per year; p=0.04).
One nonrandomized study (90) found that relatively longer exposure to antidepressants than
to mood stabilizers was associated with fewer weeks in euthymia, more mixed symptoms in
recurrences, and more polarity changes, but with uncertain cause-effect relationships. In
contrast, a 1-year randomized controlled trial of treatment of bipolar II patients who
responded initially to fluoxetine (91) found no statistical differences in risk of depressive
relapse or of syndromal or subsyndromal mania or hypomania, or in mania ratings, with
respect to prior rapid cycling or to continuation treatment with an SSRI, lithium, or placebo.
However, the study has been criticized for selecting bipolar patients with a low apparent risk
of excessive mood elevation with antidepressant treatment and for using questionable
criteria for rapid cycling (92).
Conclusions: The overall quality rating of the evidence on this topic is D. Limitations
include the prevalent exclusion of rapid-cycling bipolar patients from controlled treatment
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trials, lack of control for cycling rates, and potential confounding by lack of randomization
with treatment based on clinical need (Table 1).
Antidepressants and suicidal behavior—The question of whether antidepressants
may alter the risk of suicidal behavior in bipolar patients remains particularly uncertain, as
the evidence concerning suicide-promoting or -preventing effects of antidepressants in
bipolar disorder is limited and inconsistent (93). Two retrospective clinical studies (77, 94)
found more suicidal behaviors in patients receiving antidepressants than in those receiving
mood stabilizers with or without antidepressants. A prospective study (95) of 425 bipolar
patients treated with antidepressants for a new major depressive episode found no evidence
of more or less new suicidal ideation or behavior with antidepressant exposure. Similarly, in
789 mood disorder patients (unipolar major depression, N=605; bipolar disorder, N=184),
antidepressant treatment was not associated with altered risk of suicidal thoughts or acts,
based on changes in the suicide item of the Hamilton Depression Rating Scale at the start of
and after 3.6 months of sustained antidepressant treatment (96).
However, in 757 patients with unipolar or bipolar depression, during periods in which
patients were exposed to antidepressants, rates of suicidal behaviors appeared to be 35%–
54% lower (more in bipolar I disorder) than without antidepressant treatment (97, 98). These
observations are at odds with the proposal that antidepressant treatment may increase
suicidal risk in some young patients with unipolar depressive or anxiety disorders—
possibly by inducing agitated-dysphoric states in those with unrecognized bipolar disorder,
or as a direct toxic effect of the treatment (33, 44, 57, 99).
In 1,380 depressed bipolar I or II patients (83), the presence of subsyndromal hypomanic
symptoms was associated with more previous suicide attempts, and similar results were
found in another large study (84). Three recent studies have found an association of lifetime
mixed episodes and higher rates of antidepressant use with increased risk of suicide
behaviors (49, 50, 100). In a study of 290 patients with bipolar I or II disorder (101), suicidal
ideation or acts were found to be associated with more previous antidepressant trials (or
more depressive morbidity). Also, in a study of 138 children and adolescents diagnosed with
bipolar disorder (102), suicidal ideation and attempts were more likely in episodes of mixed
agitated-depression.
Conclusions: Overall, the evidence of an association of either decreased or increased
suicidal risk with antidepressant treatment in bipolar patients is rated D (Table 1), largely
because adequate designs are unfeasible because of the relative rarity of suicide, even
among mood disorder patients with suicidal thoughts, and because of the challenge of
designing ethical studies of effects of treatment on suicidal risk. Currently, it remains
unclear whether antidepressants might decrease or increase suicidal risk.
Consensus Statements
Based on findings from the clinical studies considered above, the available evidence
concerning both the value and the risks of antidepressant treatment in bipolar disorder is
remarkably limited, and much of it is methodologically weak. Therefore, it is not currently
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possible to make firm clinical recommendations that are soundly evidence based. There was
consensus in this ISBD Task Force that non-antidepressant treatments, including lithium,
lamotrigine, olanzapine, quetiapine, and lurasidone, should be considered as monotherapy
before using antidepressants in bipolar depression. If antidepressants are used in bipolar I
disorder, they should be prescribed along with a mood-stabilizing treatment, even though the
evidence for antidepressant-associated mood switching is mixed and the ability of mood
stabilizers to prevent such responses to antidepressant treatment unproven. Antidepressants
in the treatment of acute depression in bipolar II disorder appear to be relatively well
tolerated but may or may not be effective. Evidence for the longterm prophylactic value of
antidepressant treatment for patients with bipolar I or II disorder remains poorly studied,
despite the common clinical use of antidepressants, ideally in combination with a mood
stabilizer. There is little evidence to support the proposition that one type of antidepressant,
at clinically equivalent doses, is more or less effective or dangerous than another.
Exceptions are tri- and tetracyclics and venlafaxine, which appear to carry a particularly
high risk of inducing pathologically elevated states of mood and behavior.
In short, we conclude that the use of antidepressants to treat depressive phases or
components of bipolar disorder can neither be condemned nor endorsed without carefully
evaluating individual clinical cases and circumstances. For these reasons, the intention of
this ISBD Task Force consensus is to ascertain, as far as possible, how best to use
antidepressants to treat patients with bipolar disorder. No simple guidelines can be provided
at this time, but clinicians are encouraged to consult our consensus-based recommendations
(Table 2).We strongly encourage further research to clarify the many remaining major and
urgent clinical questions concerning optimally effective and safe treatment of depressive
components of bipolar disorder.
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TABLE 1
Summary of Average Quality and Evidence Level of Studies for Each Topic Addressed in a Review of






Antidepressant monotherapy 3 D
Adjunctive antidepressants: short-term efficacy in acute depression 4 B
Predictors of initial response to adjunctive antidepressants 3 D
Adjunctive antidepressants: maintenance studies 3.5 C
Predictors of long-term responsiveness to adjunctive antidepressant treatment 3 D
Antidepressant use in mania and mixed states 3 D
Antidepressants and affective switch (mania, hypomania, or mixed) 4 C
Are newly emerging or increasing irritability and agitation, subclinical mixed states during antidepressant treatment a
form of mood switching?
3.5 D
Antidepressants and cycle acceleration 3.5 D
Antidepressants and suicidality 3 D
a
The Jadad score is an indicator of study methodological quality (ranging from 0 to 5, with higher scores indicating higher quality). The grades for
evidence level, which also re.ect study quality, run from A (excellent) to D (poor). See the online data supplement.
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TABLE 2
International Society for Bipolar Disorders Clinical (ISBD) Recommendations for Antidepressant Use in
Bipolar Disordersa
Domain Recommendation
Acute treatment 1. Adjunctive antidepressants may be used for an acute bipolar I or II depressive episode when there is a
history of previous positive response to antidepressants.
2. Adjunctive antidepressants should be avoided for an acute bipolar I or II depressive episode with two or
more concomitant core manic symptoms in the presence of psychomotor agitation or rapid cycling.
Maintenance treatment 3. Maintenance treatment with adjunctive antidepressants may be considered if a patient relapses into a
depressive episode after stopping antidepressant therapy.
Monotherapy 4. Antidepressant monotherapy should be avoided in bipolar I disorder.
5. Antidepressant monotherapy should be avoided in bipolar I and II depression with two or more
concomitant core manic symptoms.
Switch to mania, hypomania,
or mixed states and rapid
cycling
6. Bipolar patients starting antidepressants should be closely monitored for signs of hypomania or mania
and increased psychomotor agitation, in which case antidepressants should be discontinued.
7. The use of antidepressants should be discouraged if there is a history of past mania, hypomania, or
mixed episodes emerging during antidepressant treatment.
8. Antidepressant use should be avoided in bipolar patients with a high mood instability (i.e., a high
number of episodes) or with a history of rapid cycling.
Use in mixed states 9. Antidepressants should be avoided during manic and depressive episodes with mixed features.
10. Antidepressants should be avoided in bipolar patients with predominantly mixed states.
11. Previously prescribed antidepressants should be discontinued in patients currently experiencing mixed
states.
Drug class 12. Adjunctive treatment with norepinephrine-serotonin reuptake inhibitors or tri- and tetracyclics should be
considered only after other antidepressants have been tried, and should be closely monitored because of
an increased risk of mood switch or destabilization.
a
From an initial 25 items in six domains, the 12 presented here were rated by at least 80% of ISBD experts as essential or important and were
included in the ISBD recommendations.
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